Show Summary Details
Page of

Pharmacological Interventions for Adult Anxiety Disorders 

Pharmacological Interventions for Adult Anxiety Disorders
Chapter:
Pharmacological Interventions for Adult Anxiety Disorders
Author(s):

Ryan J. Kimmel

and Peter P. Roy-Byrne

DOI:
10.1093/med/9780199395125.003.0029
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 27 October 2020

Use of benzodiazepines for the treatment of anxiety dates back almost 60 years, and the efficacy of monoamine-reuptake inhibition-based interventions in anxiety disorders has been established for over 50 years. Currently, a more specific type of monoamine reuptake inhibitor, the SSRI, is now well accepted as a first-line treatment. Though the DSM-5 divides anxiety disorders, obsessive compulsive disorders, and trauma-related disorders into separate chapters, serotonergic compounds still demonstrate efficacy across this spectrum of anxiety, in contrast to the more limited efficacy of benzodiazepines. The value of medications that target other receptor systems varies by diagnosis, as do pharmacologic augmentation strategies and overall rates of response to the SSRIs. The variability of response to various interventions among the disorders in the anxiety spectrum suggests that it is imperative to make a clear diagnosis, identify specific symptomatology that might be amenable to a specific treatment, and then track treatment results closely.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.